Home › Metastatic Cancer › Michigan
Metastatic Cancer clinical trials in Michigan
48 studies for Metastatic Cancer are looking for participants at sites in Michigan.
Cities in Michigan
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, Detroit
- Clinical Study Site, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07335497A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06270706Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- and 39 more
RecruitingPhase 2
All ages · All sexes · Updated Nov 12, 2026 · NCT05564377A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- University of Michigan, Ann Arbor
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- University of Michigan Rogel Cancer Center, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07007559A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Henry Ford Cancer Institute, Detroit
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Nov 6, 2026 · NCT05384626A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07029399A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06465069A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Karmanos Cancer Institute, Detroit
- West Michigan Cancer Center, Kalamazoo
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07213804A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health Inc., Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07114601A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- University of Michigan, Ann Arbor
- The Cancer & Hematology Centers, Grand Rapids
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06119581FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Barbara Ann Karmanos Cancer Institute, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05614739Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Henry Ford Cancer Institute, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05856981A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
- START Midwest, LLC, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07903415Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Henry Ford Cancer- Detroit, Detroit
- The Cancer and Hematology Centers, Grand Rapids
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06943755A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07094204A Study of MGC026 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06242470A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06769698Collection and Storage of Tissue and Blood Samples From Patients With Cancer
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
RecruitingObservational study
2 Months · All sexes · Updated Oct 22, 2026 · NCT02474160A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
- Henry Ford Cancer Center, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06521554A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- Karmanos Cancer Institute, Detroit
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT06244771Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- Karmanos Cancer Institute, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06915753A Study of ASP3082 in Adults With Advanced Solid Tumors
- Trinity Health Ann Arbor Hospital, Ypsilanti
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT05382559A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06880549Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Henry Ford Health System, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06757634A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- University of Michigan ( Site 0021), Ann Arbor
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06863272Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- The Cancer & Hematology Centers, Big Rapids
- The Cancer & Hematology Centers, Grand Rapids
- The Cancer & Hematology Centers, Grand Rapids
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07222800A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Karmanos Cancer Institute, Detroit
- Brigitte Harris Cancer Pavilion, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT07218380A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07213817A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 8, Farmington Hills
- ALX Center 3, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07085091A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06103864A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Henry Ford Cancer Institute, Detroit
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 24, 2026 · NCT05118789Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- University of Michigan Medical School Rogel Cancer Center, Ann Arbor
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07629960Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
- South Texas Accelerated Research Therapeutics (START) - Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07213830Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Ann Arbor
- Research Site, Ann Arbor
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #120, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT06974110A Study of ASP1002 in Adults for Treatment of Solid Tumors
- Henry Ford Hospital, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT05719558A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Henry Ford Health System, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT06657144From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.